.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Novartis
Citi
Healthtrust
Accenture
Julphar
US Department of Justice
Chinese Patent Office
Cantor Fitzgerald
Daiichi Sankyo

Generated: November 19, 2017

DrugPatentWatch Database Preview

Suppliers and packages for generic ingredient: nilotinib hydrochloride monohydrate

« Back to Dashboard

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package
Novartis
TASIGNA
nilotinib hydrochloride monohydrate
CAPSULE;ORAL022068NDANovartis Pharmaceuticals Corporation0078-0526-5128 CAPSULE in 1 BLISTER PACK (0078-0526-51)
Novartis
TASIGNA
nilotinib hydrochloride monohydrate
CAPSULE;ORAL022068NDANovartis Pharmaceuticals Corporation0078-0526-874 BLISTER PACK in 1 CARTON (0078-0526-87) > 28 CAPSULE in 1 BLISTER PACK
Novartis
TASIGNA
nilotinib hydrochloride monohydrate
CAPSULE;ORAL022068NDANovartis Pharmaceuticals Corporation0078-0592-5128 CAPSULE in 1 BLISTER PACK (0078-0592-51)
Novartis
TASIGNA
nilotinib hydrochloride monohydrate
CAPSULE;ORAL022068NDANovartis Pharmaceuticals Corporation0078-0592-874 BLISTER PACK in 1 CARTON (0078-0592-87) > 28 CAPSULE in 1 BLISTER PACK
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
UBS
Boehringer Ingelheim
Queensland Health
Daiichi Sankyo
Chubb
Mallinckrodt
Citi
Chinese Patent Office
Moodys

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot